SCHEMBL5368693

SCHEMBL5368693

CCOC(=O)c1cc(C=C2C(=O)Nc3ccc(Br)c(C)c32)oc1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.39
KDM4E B2RXH2 2/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
HPGD P15428 1/20 0.39
RECQL P46063 1/20 0.39
KMT2A Q03164 1/20 0.39
MCL1 Q07820 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KDR P35968 2/20 0.38
PDGFRB P09619 2/20 0.38
FGFR1 P11362 2/20 0.38
RET P07949 2/20 0.38
ABL1 P00519 1/20 0.38
FLT3 P36888 1/20 0.38
ALK Q9UM73 1/20 0.38
MAOB P27338 2/20 0.37
BRAF P15056 1/20 0.36
GSK3B P49841 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7137028 0.85 MAOB (0.38) MAPTKDM4EMEN1ALDH1A1POLB
SCHEMBL5358671 0.81 RET (0.39) MAPTMEN1ALDH1A1POLBRECQL
SCHEMBL6001584 0.79 KDR (0.60) MAPTMEN1ALDH1A1POLBRECQL
SCHEMBL6001577 0.79 KDR (0.60) MAPTMEN1ALDH1A1POLBRECQL
SCHEMBL5373574 0.79 MAPT (0.45) MAPTKDM4EMEN1ALDH1A1POLB
SCHEMBL5373671 0.76 GSK3B (0.44) MAPTKDM4EMEN1ALDH1A1POLB
SCHEMBL5368918 0.76 PDGFRB (0.66) MAPTKDM4EMEN1KMT2AKDR
SCHEMBL5367226 0.74 PTPN1 (0.44) MAPTMEN1ALDH1A1POLBKMT2A
SCHEMBL5367431 0.73 RET (0.55) MAPTKDM4EMEN1ALDH1A1POLB
SCHEMBL5364403 0.73 KMT2A (0.56) MAPTKDM4EMEN1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK MAPT 3048/4885KDM4E 2527/4885MEN1 3855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.